Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Progenitor Inc
PGEN | US
4.16
USD-0.11
-2.58%
PGEN | US
About Progenitor Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
4.16
Open
4.30
High
4.37
Low
4.07
Precigen Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15 a gene that enhances functional characteristics of immune cells; Sleeping Beauty a non-viral transposon/transposase system; AttSite recombinases which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform a library of engineered adenovector serotypes; and Lactococcus lactis a food-grade bacterium. Additionally it provides RheoSwitch Therapeutic System an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen Inc. has collaboration and license agreements with Alaunos Therapeutics Inc.; Intrexon Energy Partners LLC; and Intrexon Energy Partners II LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen Inc. in January 2020. Precigen Inc. was founded in 1998 and is headquartered in Germantown Maryland.
View LessPGEN | US
Risk
128.0
Sharpe
2.37
Luna's Score
54/100
Recommendation
Hold
Luna says (PGEN | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
127.8%1 month
128.0%3 months
96.8%6 months
92.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
9.14
Price to book
6.46
Debt to equity
0.15
Debt to assets
0.09
Ent. to EBITDA
-3.31
Ent. to rev.
60.54
PEG
-
Other Fundamentals
EBITDA
-88.58M
MarketCap
1.22B
MarketCap(USD)
1.22B
Div. yield
-
Op. margin
-3.67K
Erngs. growth
-
Rev. growth
-59.40
Ret. on equity
-129.32
Short ratio
18.16
Short perc.
8.19
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.15
Range1M
1.33
Range3M
2.43
Volumes: Market Activity
Rel. volume
0.52
Price X volume
11.75M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.31 | - | Cheaper |
| Ent. to Revenue | 60.54 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.46 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 96.77 | - | Riskier |
| Debt to Equity | 0.15 | -1.23 | Expensive |
| Debt to Assets | 0.09 | 0.25 | Cheaper |
| Market Cap | 1.22B | - | Emerging |
